"Doxorubicin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of DAUNORUBICIN.
| Descriptor ID |
D004317
|
| MeSH Number(s) |
D02.455.426.559.847.562.050.200.175 D04.615.562.050.200.175 D09.408.051.059.200.175
|
| Concept/Terms |
Adriblastin- Adriblastin
- Adriblastine
- Adriblastina
- Adriablastine
- Adriablastin
DOXO-cell- DOXO-cell
- DOXO cell
- Urokit Doxo-cell
- Urokit Doxo cell
|
Below are MeSH descriptors whose meaning is more general than "Doxorubicin".
Below are MeSH descriptors whose meaning is more specific than "Doxorubicin".
This graph shows the total number of publications written about "Doxorubicin" by people in this website by year, and whether "Doxorubicin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 2 | 2 | 4 |
| 1996 | 0 | 4 | 4 |
| 1997 | 2 | 1 | 3 |
| 1998 | 0 | 4 | 4 |
| 1999 | 0 | 1 | 1 |
| 2000 | 1 | 2 | 3 |
| 2001 | 4 | 6 | 10 |
| 2002 | 1 | 1 | 2 |
| 2003 | 0 | 3 | 3 |
| 2004 | 1 | 8 | 9 |
| 2005 | 0 | 7 | 7 |
| 2006 | 2 | 4 | 6 |
| 2007 | 2 | 7 | 9 |
| 2008 | 1 | 2 | 3 |
| 2009 | 0 | 6 | 6 |
| 2010 | 5 | 5 | 10 |
| 2011 | 3 | 5 | 8 |
| 2012 | 4 | 8 | 12 |
| 2013 | 1 | 7 | 8 |
| 2014 | 4 | 4 | 8 |
| 2015 | 4 | 5 | 9 |
| 2016 | 2 | 6 | 8 |
| 2017 | 2 | 5 | 7 |
| 2018 | 0 | 3 | 3 |
| 2019 | 2 | 6 | 8 |
| 2020 | 1 | 2 | 3 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 1 | 1 |
| 2023 | 0 | 6 | 6 |
| 2024 | 1 | 3 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Doxorubicin" by people in Profiles.
-
Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer. Breast Cancer Res Treat. 2025 Feb; 209(3):487-492.
-
Sonopermeation With Size-sorted Microbubbles Synergistically Increases Survival and Enhances Tumor Apoptosis With L-DOX by Increasing Vascular Permeability and Perfusion in Neuroblastoma Xenografts. Ultrasound Med Biol. 2025 02; 51(2):348-357.
-
Protocol-Stipulated Dose Modification to Manage Chemotherapy-Induced Peripheral Neuropathy in Children, Adolescents, and Young Adults With High-Risk Hodgkin Lymphoma. JCO Oncol Pract. 2025 Apr; 21(4):526-534.
-
Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec; 30(12):3728-3736.
-
Datopotamab-deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec; 30(12):3737-3747.
-
CD5 Gene Signature Identifies Diffuse Large B-Cell Lymphomas Sensitive to Bruton's Tyrosine Kinase Inhibition. J Clin Oncol. 2024 Feb 01; 42(4):467-480.
-
High-grade B-cell lymphoma, not otherwise specified: a multi-institutional retrospective study. Blood Adv. 2023 11 14; 7(21):6381-6394.
-
Optical Diffraction Tomography and Raman Confocal Microscopy for the Investigation of Vacuoles Associated with Cancer Senescent Engulfing Cells. Biosensors (Basel). 2023 Nov 07; 13(11).
-
Podocyte injury at young age causes premature senescence and worsens glomerular aging. Am J Physiol Renal Physiol. 2024 01 01; 326(1):F120-F134.
-
Subsequent female breast cancer risk associated with anthracycline chemotherapy for childhood cancer. Nat Med. 2023 09; 29(9):2268-2277.